• Reflecting on why preclinical mechanisms often fail in the clinic and exploring new ways to rethink PARP inhibitor mechanisms and dosing strategies

• Debating whether current success metrics in DDR drug development align with meaningful patient outcomes and explore shifting the focus to long-term benefit and resistance avoidance

• Sharing cross-disciplinary perspectives on how biomarkers, experimental tools, and trial design innovations can advance precision medicine